We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
Read MoreHide Full Article
Abbott Laboratories (ABT - Free Report) has witnessed strong momentum in the past year. Shares of the company have risen 12.7% compared with the 9% growth of the industry during the same time frame. The S&P 500 Composite has increased 10%.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Abbott discovers, develops, manufactures and sells a diversified line of healthcare products. The company has four reportable segments, namely, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. Its Established Pharmaceuticals Division includes the branded generics business in emerging markets and its Medical Devices segment includes the diabetes care, vision care and vascular businesses. Within the Diagnostics segment, Abbott manufactures and markets diagnostic systems and tests in four business lines — core laboratory, molecular, point of care and rapid diagnostics. Meanwhile, the Nutrition business includes a broad line of pediatric and adult nutritional products.
Factors Favoring ABT’s Share Price Growth
Abbott’s share price is trending upward, prompted by the strong prospects within the Core Diagnostics business. The company continues to expand its Diagnostics business foothold. It is witnessing increased global demand for its routine diagnostic. It is particularly gaining from strong demand for its portfolio of respiratory disease tests.
In rapid and point-of-care diagnostics businesses, the company is successfully expanding its test menus and is also capitalizing on the growing demand for respiratory tests that can be performed at home or in more traditional healthcare settings. In lieu of this, rapid diagnostics sales (excluding COVID-19 testing sales) increased 16% year over year. Additionally, the Core Laboratory Diagnostics business grew 4%, driven by continued strong demand for Abbott’s immunoassay, clinical chemistry, hematology and blood screening testing panels. This increased optimism among investors and is expected to contribute further.
Investors showed optimism about Abbott’s growing sales of its flagship, sensor-based, continuous glucose monitoring system, FreeStyle Libre. FreeStyle Libre has achieved global leadership among continuous glucose monitoring systems for both Type 1 and Type 2 users. Of late, the company is fast gaining momentum, leveraging consistent upgrades of FreeStyle Libre.
Abbott’s sales recovery within the Nutrition business looks encouraging. The business consistently demonstrates strong growth and market share gains. The overall Nutrition business is particularly expanding on strong global demand for the company’s adult nutrition products like Ensure and Glucerna. In the fourth quarter of 2024, the company reported 7.1% organic growth within this business backed by a strong 11.4% growth in Adult Nutrition.
Factors That May Offset ABT’s Gains
In the fourth quarter, Abbott incurred an 8.5% increase in the cost of products. The gross margin contracted 55 basis points to 55%. Selling, general and administration expenses were up 6.7% year over year, resulting in a 43-basis-point contraction in the adjusted operating margin. This was due to the ongoing complex geopolitical situation globally and the deteriorating global economic environment, which is reducing demand for several products, resulting in increased costs of goods and operating expenses of the businesses of the company.
Image Source: Zacks Investment Research
Further, Abbott remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters. In the fourth quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales.
A Look at ABT’s Estimates
The Zacks Consensus Estimate for 2025 EPS has remained unchanged at $5.15 in the past 30 days.
Abbott has an earnings yield of 4.1% compared with the industry’s 0.4%.
Phibro Animal Health has an earnings yield of 8.2%, well ahead of the industry’s 1.2%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 27.06%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
Masimo, presently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.5%, well ahead of the industry’s -3.6%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 14.4%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 10.7% compared with the industry’s 9.4%. Shares of the company have rallied 12.1% against the industry’s 2.3% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
Abbott Laboratories (ABT - Free Report) has witnessed strong momentum in the past year. Shares of the company have risen 12.7% compared with the 9% growth of the industry during the same time frame. The S&P 500 Composite has increased 10%.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Abbott discovers, develops, manufactures and sells a diversified line of healthcare products. The company has four reportable segments, namely, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. Its Established Pharmaceuticals Division includes the branded generics business in emerging markets and its Medical Devices segment includes the diabetes care, vision care and vascular businesses. Within the Diagnostics segment, Abbott manufactures and markets diagnostic systems and tests in four business lines — core laboratory, molecular, point of care and rapid diagnostics. Meanwhile, the Nutrition business includes a broad line of pediatric and adult nutritional products.
Factors Favoring ABT’s Share Price Growth
Abbott’s share price is trending upward, prompted by the strong prospects within the Core Diagnostics business. The company continues to expand its Diagnostics business foothold. It is witnessing increased global demand for its routine diagnostic. It is particularly gaining from strong demand for its portfolio of respiratory disease tests.
In rapid and point-of-care diagnostics businesses, the company is successfully expanding its test menus and is also capitalizing on the growing demand for respiratory tests that can be performed at home or in more traditional healthcare settings. In lieu of this, rapid diagnostics sales (excluding COVID-19 testing sales) increased 16% year over year. Additionally, the Core Laboratory Diagnostics business grew 4%, driven by continued strong demand for Abbott’s immunoassay, clinical chemistry, hematology and blood screening testing panels. This increased optimism among investors and is expected to contribute further.
Investors showed optimism about Abbott’s growing sales of its flagship, sensor-based, continuous glucose monitoring system, FreeStyle Libre. FreeStyle Libre has achieved global leadership among continuous glucose monitoring systems for both Type 1 and Type 2 users. Of late, the company is fast gaining momentum, leveraging consistent upgrades of FreeStyle Libre.
Abbott’s sales recovery within the Nutrition business looks encouraging. The business consistently demonstrates strong growth and market share gains. The overall Nutrition business is particularly expanding on strong global demand for the company’s adult nutrition products like Ensure and Glucerna. In the fourth quarter of 2024, the company reported 7.1% organic growth within this business backed by a strong 11.4% growth in Adult Nutrition.
Factors That May Offset ABT’s Gains
In the fourth quarter, Abbott incurred an 8.5% increase in the cost of products. The gross margin contracted 55 basis points to 55%. Selling, general and administration expenses were up 6.7% year over year, resulting in a 43-basis-point contraction in the adjusted operating margin. This was due to the ongoing complex geopolitical situation globally and the deteriorating global economic environment, which is reducing demand for several products, resulting in increased costs of goods and operating expenses of the businesses of the company.
Image Source: Zacks Investment Research
Further, Abbott remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the last few quarters. In the fourth quarter of 2024, foreign exchange had an unfavorable year-over-year impact of 1.4% on sales.
A Look at ABT’s Estimates
The Zacks Consensus Estimate for 2025 EPS has remained unchanged at $5.15 in the past 30 days.
Abbott has an earnings yield of 4.1% compared with the industry’s 0.4%.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Masimo (MASI - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health has an earnings yield of 8.2%, well ahead of the industry’s 1.2%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 27.06%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo, presently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.5%, well ahead of the industry’s -3.6%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 14.4%. Its shares have surged 45.3% against the industry’s 2.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 10.7% compared with the industry’s 9.4%. Shares of the company have rallied 12.1% against the industry’s 2.3% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%.